FI80719B - Foerfarande foer framstaellning av maenniskointerferonpolypeptider. - Google Patents
Foerfarande foer framstaellning av maenniskointerferonpolypeptider. Download PDFInfo
- Publication number
- FI80719B FI80719B FI823356A FI823356A FI80719B FI 80719 B FI80719 B FI 80719B FI 823356 A FI823356 A FI 823356A FI 823356 A FI823356 A FI 823356A FI 80719 B FI80719 B FI 80719B
- Authority
- FI
- Finland
- Prior art keywords
- leu
- dna
- ser
- glu
- gln
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (9)
1. Förfarande för framställning av en människointerfe-ron-polypeptid, som är HLycIFN-1'b, som kodas av ett inklo-nat DNA-fragment med sekvensen ATGGCCCTGTCCTTTTCTTTACCGATGCCCGTGCTGGTGCTCAGCCACAAATCCATCTGT tctctgggctgtcatctgcctcagacccacagcctgggtaataggagggccttgatactcctggcaca aatgggaagaatcccccctttctcctgcctgaaggacagacatgactttggatttccccaggaggagt ttgatggcaaccagttccagaaggctcaagccatctctctcctccatgagatgatccagcacaccttc aatctcttcagcacaaaggactcatctgctacttgggaacagagcctcctagaaaaattttccactga acttaaccagcagctgaatgacctggaagcctgcgtgatacaggaggttggggtggaagagactcccc tgatgaatgiggactccatcctggctgtgaagaaatacttccaaagaatcactctttatctgacagag aagaaatacagcccttgtgcctgggaggttgtcacaccagaaatcatgagatccttctctttatcaaa AA7TTTTCAACAAAGATTAAGGACGAACGAATGA, HLycIFN-S^, som kodas av ett inklonat DNA-fragment med sekvensen ATGGCCTTGACTTTTTATTTACTGGTGCCCC TAGTGGTGCTCAGCTACAAGTCATTCAGCXCTCTGGGCTGTGATCTGCCTCAGACTCACAGCCTGGG TAACAGGAGGGCCTTGATACTCCTGGCACAAATGCGAAGAATCTCTCCTTTCTCCTGCCTGAAGCAC AGACATGACTTTGAATTCCCCCAGGAGGAGTTTGATGATAAACAGTTCCAGAAGGCTCAAGCCATCT CTGTCCTCCATGAGATGATCCAGCAGACCTTCAACCTCTTCAGCACAAAGGACTCATCTGCTGCTTT GGATGAGACCCTTCTAGATGAATICTACATCGAACTTGACCAGCAGCTGAATGACCTCGAG TCCTGTGTGATGCAGGAAGTGGGGGTGATAGAGTCTCCCCTGATGTACGAGGACTCCATCCTGGCTG TGAGGAAATACTTCCAAAGAATCACTCTATATCTGACAGAGAAGAAATACAGCTCTTGTGCCTGGGA GGTTGTCAGAGCAGAAATCATGAGATCCTTCTCTTTATCAATCAACTTGCAAAAAAGATTGAAGAGT AAGGAATGA, LyIFN-a-1, som kodas av ett inklonat DNA-fragment med sekvensen ÄTGTCTGATCTGCCTCA GACCCACAGCCTGGGTAATAGGAGGGCCTTGATACTCCTGGCACAAATGGGAACAATCCCCCCTTTC tcctgcctgaaggacagacatgactttggaxttccccaggaggactttgatggcaaccagttccaga AGGCTCAA GCCATCTCTGTCCTCCATGAGATGATCCAGCAGACCTTCAATCTCTTCAGCACAAACG actcatctgctacttgggaacagagcctcctagaaaaattttccactgaacttaaccagcagctgaa tgacctggaagcctgcgtgatacaggaggttggggtggaagagactcccctgatgaatgtggactcc atcctggctgtgaagaaatacttccaaagaatcactctttatctgacagagaagaaatacagccctt gtgcctgggaggttgtcagagcagaaatcatgagatccttctctttatcaaaaatttttcaacaaag ATTAAGGAGGAAGGAATGA 94 8071 9 e Her LyIFN-a-2, som kodas av ett inklor.at DNA-fragment med sekvensen ATGTGTGATCTGCCTC AGACTCACAGCCTGGGTAACAGGAGGGCCTTGATACTCCTGGCACAAATGCGAAGAATCTCTCCTT TCTCCTGCCTGAACGACAGACATGACTTTGAATTCCCCCAGGAGGAGTTTGATGATAAACAGTTCC AGAAGGCTCAAGCCATCTCTGTCCTCCATGAGATGATCCAGCAGäCCTTCAACCTCTTCAGCaCAA AGGACTCATCTGCTGCTTTGGATGAGACCCTTCTAGATGAATTCTACATCGAACTTGACCAGCAGC TCAATGACCTGGACTCCTCTGTGATGCAGGAAGTCGGGGTGATAGAGTCTCCCCTGATGTACGAGG ACTCCATCCTGGCTGTGAGGAAATACTTCCAAAGAATCACTCTATATCTCACAGACAACAAATACA GCTCTTCTGCCTGGGAGGTTGTCAGAGCAGAAATCATCAGATCCTTCTCrTTATCAATCAACTTGC AAAAAACATTCAACAGTAACCAATGA , kännetecknat därav, att man odlar en jäst- eller E. coli-värd, som är transformerad med minst ett hybrid-DNA, som innehäller vilket som heist av de nämnda DNA-fragmenen, och den nämnda polypeptiden tillvaratas frän odlingsmediet.
2. Förfarande enligt patentkravet 1, kännetecknat därav, att man producerar HLycIFN-1'b med sekvensen MET ALA LEU SER PHE SER LEU LED KET ALA VAL LEU VAL LEU SER TYR LYS SER ILE CYS SER LEU GLY CYS ASP LEU PRO GLN THR HIS SER LEU CLY ASN ARG ARG ALA LEU ILE LEU LEU ALA GLN MET CLY ARG ILE PRO PRO PHE SER CYS LEU LYS ASP ARC HIS ASP PHE GLY PHE PRO GLN GLU GLU PHE ASP GLY ASN GLN PHE GLN LYS ALA GLN ALA ILE SER VAL LEU HI S GLU MET ILE GLN GLN THR PHE ASN LEU PHE SER THR LYS ASP SER SER ALA THR TRP GLU GLN SER LEU LEU GLU LYS PHE SER THR GLU LEU ASN GLN GLN LEU ASN ASP LEU GLU ALA CYS VAL ILE GLN GLU VAL GLY VAL GLU GLU THR PRO LEU MET ASN VAL ASP SER ILE LEU ALA VAL LYS LYS TYR PHE GLN ARG ILE THR LEU TYR LEU THR GLU LYS LYS TYR SER PRO CYS AU TRP GLU VAL VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER LYS ILE PHE GLN GLU ARG LEU ARG ARG LYS GLU
3. Förfarande enligt patentkravet 1, kännetecknat därav, att man producerar HLycIFN-5^ med sekvensen 95 80719 MET ALA LEU THR PHE TYR LEU LEU VAL ALA LEU VAL VAL LEU SER TYR LYS SER PHE SER SER LEU GLY CYS ASP LEU PRO GLN THR HIS SER LEU CLY ASN ARC ARC ALA LEU ILE LEU LEU ALA GLN MET ARC ARC ILE SER PRO PHE SER CYS LEU LYS ASP ARC BIS ASP PHE GLU PHE PRO GLN GLU GLU PHE ASP ASP LYS GLN PHE GLN LYS ALA GLN ALA ILE SER VAL LEU HIS GLU MET ILE GLN GLN THR PHE ASN LEU PHE SER THR LYS ASP SER SER ALA ALA LEU ASP GLU THR LEU LEU AS? GLU PHE TYR ILE GLU LEU ASP GLN GLN LEU ASN ASP LEU GLU SER CYS VAL MET GLN GLU VAL GLY VAL ILE GLU SER PRO LEU MET TYR GLU ASP SER ILE LEU ALA VAL ARC LYS TYR PHE GLN ARG ILE THR LEU TYR LEU THR GLU LYS LYS TYR SER SER CYS ALA TRP GLU VAL VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER ILE ASN LEU GLN LYS ARG LEU LYS SER LYS GLU
4. Förfarande enligt patentkravet 1, känne-t e c k n a t därav, att man producerar LyIFN-a-1.
5. Förfarande enligt patentkravet 1, känne-t e c k n a t därav, att man producerar LyIFN-a-2.
6. Förfarande enligt patentkravet 1, känne-t e c k n a t därav, att den transformerade värden är E. coli HB 101 CG-pBR322/HLycIFN-l'b (NRRL B-12530).
7. Förfarande enligt patentkravet 1, känne-t e c k n a t därav, att den transformerade värden är E. coli HB 101 CG-pBR322/HLycIFN-51 (NRRL B-12531).
8. Förfarande enligt patentkravet 1, kanne-t e c k n a t därav, att den transformerade värden är E. coli HB 101 CG-pBR(AP)/LyIFN-a-1.
9. Förfarande enligt patentkravet 1, känne-t e c k n a t därav, att den transformerade värden är E. coli HB 101 CG-pBR(AP)/LyIFN-a-2.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8129937 | 1981-10-03 | ||
| GB8129937 | 1981-10-03 | ||
| GB8208988 | 1982-03-26 | ||
| GB8208988 | 1982-03-26 | ||
| GB8224871 | 1982-09-01 | ||
| GB08224871A GB2108510B (en) | 1981-10-03 | 1982-09-01 | Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI823356A0 FI823356A0 (fi) | 1982-10-01 |
| FI823356L FI823356L (fi) | 1983-04-04 |
| FI80719B true FI80719B (fi) | 1990-03-30 |
| FI80719C FI80719C (sv) | 1990-07-10 |
Family
ID=27261323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI823356A FI80719C (sv) | 1981-10-03 | 1982-10-01 | Förfarande för framställning av människointerferonpolypeptider |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5089400A (sv) |
| EP (1) | EP0076489B1 (sv) |
| JP (2) | JPH06104066B2 (sv) |
| KR (1) | KR920007665B1 (sv) |
| AU (1) | AU561104B2 (sv) |
| DD (1) | DD204266A5 (sv) |
| DE (1) | DE3280174D1 (sv) |
| DK (1) | DK170714B1 (sv) |
| ES (2) | ES8504936A1 (sv) |
| FI (1) | FI80719C (sv) |
| GB (1) | GB2108510B (sv) |
| GR (1) | GR76992B (sv) |
| HU (1) | HU197047B (sv) |
| IE (1) | IE54051B1 (sv) |
| IL (1) | IL66920A0 (sv) |
| NO (1) | NO166494C (sv) |
| NZ (1) | NZ202058A (sv) |
| PH (2) | PH21524A (sv) |
| PT (1) | PT75643B (sv) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2108510B (en) * | 1981-10-03 | 1984-12-12 | Ciba Geigy Ag | Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof |
| DE3220116A1 (de) | 1982-05-28 | 1983-12-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung |
| JPS59501866A (ja) * | 1982-10-11 | 1984-11-08 | ナショナル・リサ−チ・ディベロップメント・コ−ポレイション | 腸内ウイルスに対するワクチン接種に有用なポリペプチド |
| CA1252046A (en) * | 1982-11-04 | 1989-04-04 | Martin J. Cline | Methods for oncogenic detection |
| JPS60118196A (ja) * | 1983-11-30 | 1985-06-25 | Takeda Chem Ind Ltd | インタ−フェロンの製造法 |
| JPS6156199A (ja) * | 1984-08-27 | 1986-03-20 | Shionogi & Co Ltd | 新規ヒトインタ−フエロンα類 |
| DE3685044D1 (de) * | 1985-02-01 | 1992-06-04 | Ici Plc | Analoge interferon-polypeptide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
| GB8508685D0 (en) * | 1985-04-03 | 1985-05-09 | Minor P D | Peptides |
| IE58766B1 (en) * | 1985-04-30 | 1993-11-03 | Takeda Chemical Industries Ltd | Production of protein |
| US4885166A (en) * | 1985-06-11 | 1989-12-05 | Ciba-Geigy Corporation | Hybrid interferons |
| DE3751409T2 (de) | 1986-04-15 | 1996-01-25 | Ciba Geigy Ag | Monoklonale Antikörper gegen Interferon-induziertes humanes Protein in gereignigter Form, und diese Antikörper enthaltende Testsätze. |
| TW218846B (sv) * | 1992-04-07 | 1994-01-11 | Ciba Geigy | |
| US5733733A (en) * | 1992-08-04 | 1998-03-31 | Replicon, Inc. | Methods for the isothermal amplification of nucleic acid molecules |
| US6261808B1 (en) | 1992-08-04 | 2001-07-17 | Replicon, Inc. | Amplification of nucleic acid molecules via circular replicons |
| US5834202A (en) * | 1992-08-04 | 1998-11-10 | Replicon, Inc. | Methods for the isothermal amplification of nucleic acid molecules |
| WO1994003624A1 (en) * | 1992-08-04 | 1994-02-17 | Auerbach Jeffrey I | Methods for the isothermal amplification of nucleic acid molecules |
| US20020102236A1 (en) * | 1994-12-08 | 2002-08-01 | Taylor Peter William | Liposomal interferon hybrid compositions |
| WO1996024678A1 (en) | 1995-02-09 | 1996-08-15 | Novartis Ag | Process for the production of proteins |
| US6087102A (en) * | 1998-01-07 | 2000-07-11 | Clontech Laboratories, Inc. | Polymeric arrays and methods for their use in binding assays |
| US6685933B1 (en) | 1998-07-28 | 2004-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon α hybrids |
| DE19919149A1 (de) * | 1999-04-27 | 2000-11-16 | Wieser Raimund J | Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere |
| EP2292652A2 (en) * | 2000-11-03 | 2011-03-09 | Pestka Biomedical Laboratories, Inc. | Interferons uses and compositions related thereto |
| WO2002088161A1 (en) * | 2001-05-02 | 2002-11-07 | Pepgen Corporation | Method for expression of human interferon alpha 1 in pichia pa storis |
| FR2825716B1 (fr) | 2001-06-11 | 2004-09-24 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'ifn alpha 7 |
| CA2591235C (en) * | 2004-12-20 | 2014-03-11 | Cadila Healthcare Limited | Process for preparing high levels of interferon beta |
| WO2018092905A1 (ja) | 2016-11-21 | 2018-05-24 | 日東電工株式会社 | 粘着シート |
| KR102202222B1 (ko) | 2016-11-21 | 2021-01-13 | 닛토덴코 가부시키가이샤 | 점착 시트 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA796175B (en) * | 1978-11-24 | 1980-11-26 | Hoffmann La Roche | Purified proteins and process therefor |
| AU538665B2 (en) * | 1979-10-30 | 1984-08-23 | Juridical Foundation, Japanese Foundation For Cancer Research | Human interferon dna |
| ES8308534A1 (es) * | 1980-01-08 | 1983-09-01 | Biogen Nv | Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos. |
| DE3005897A1 (de) * | 1980-02-16 | 1981-09-03 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus |
| FI88175C (sv) * | 1980-04-03 | 1993-04-13 | Biogen Inc | Rekombinant-DNA-molekyler och förfaranden för framställning av polypep tider liknande humant -interferon |
| ATE25985T1 (de) * | 1980-06-12 | 1987-04-15 | Japan Found Cancer | Plasmid. |
| ES8302778A1 (es) * | 1980-11-10 | 1983-02-01 | Genentech Inc | Un procedimiento para producir un polipeptido antiviral. |
| GB2108510B (en) * | 1981-10-03 | 1984-12-12 | Ciba Geigy Ag | Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof |
-
1982
- 1982-09-01 GB GB08224871A patent/GB2108510B/en not_active Expired
- 1982-09-30 IL IL66920A patent/IL66920A0/xx unknown
- 1982-09-30 KR KR8204446A patent/KR920007665B1/ko active
- 1982-10-01 ES ES516154A patent/ES8504936A1/es not_active Expired
- 1982-10-01 DE DE8282109094T patent/DE3280174D1/de not_active Expired - Lifetime
- 1982-10-01 DD DD82243742A patent/DD204266A5/de not_active IP Right Cessation
- 1982-10-01 PH PH27947A patent/PH21524A/en unknown
- 1982-10-01 IE IE2385/82A patent/IE54051B1/en not_active IP Right Cessation
- 1982-10-01 EP EP82109094A patent/EP0076489B1/de not_active Expired - Lifetime
- 1982-10-01 HU HU823164A patent/HU197047B/hu not_active IP Right Cessation
- 1982-10-01 NO NO823314A patent/NO166494C/no unknown
- 1982-10-01 PT PT75643A patent/PT75643B/pt not_active IP Right Cessation
- 1982-10-01 FI FI823356A patent/FI80719C/sv not_active IP Right Cessation
- 1982-10-01 NZ NZ202058A patent/NZ202058A/en unknown
- 1982-10-01 AU AU88958/82A patent/AU561104B2/en not_active Ceased
- 1982-10-01 GR GR69416A patent/GR76992B/el unknown
- 1982-10-01 DK DK437382A patent/DK170714B1/da not_active IP Right Cessation
- 1982-10-04 JP JP57174426A patent/JPH06104066B2/ja not_active Expired - Lifetime
-
1983
- 1983-12-16 ES ES528141A patent/ES8601237A1/es not_active Expired
-
1985
- 1985-06-26 PH PH32461A patent/PH23119A/en unknown
-
1989
- 1989-03-07 US US07/320,185 patent/US5089400A/en not_active Expired - Fee Related
-
1994
- 1994-07-05 JP JP6153677A patent/JP2612149B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI80719B (fi) | Foerfarande foer framstaellning av maenniskointerferonpolypeptider. | |
| JP2558422B2 (ja) | インターフェロンをコードする遺伝子 | |
| JP2882775B2 (ja) | ヒトーグリア由来神経突起因子 | |
| KR920001377B1 (ko) | 인체 면역 인터페론 단백질의 제조방법 | |
| CA1212915A (en) | Process for the preparation of hybrid human leukocyte interferons | |
| KR870001224B1 (ko) | 생리활성 펩티드를 생산하는 형질전환체의 제조방법 | |
| US5541312A (en) | Production of interferon | |
| JP2687995B2 (ja) | Ｄｎａ配列、組替えｄｎａ分子およびヒト繊維芽細胞インターフェロン様ポリペプチドの製造方法 | |
| HU193512B (en) | Process for preparing hybride interferones from human erythrocytes | |
| CS273152B2 (en) | Method of mature human leucocytic interferon production | |
| CZ282154B6 (cs) | Lidský imunitní interferon a jeho derivát, isolát DNA se sekvencí kodující lidský imunitní interferon, rekombinantní klonovací vektor, replikovatelný expresní vektor, rekombinantní mikroorganismus nebo buněčná kultura, farmaceutický přípravek, způsob výroby lidského imunitního interferonu a jeho použití | |
| EP0133321B1 (en) | Dna gene, process for production thereof and plasmid containing the same | |
| EP0242329B1 (en) | Monoclonal antibodies against interferon-induced human protein in pure form, and test kits containing these antibodies | |
| JPH0822230B2 (ja) | アルファ―インターフェロンｇｘ―１ | |
| JPS60126299A (ja) | 新規インターフェロンγとその製造方法 | |
| US5656596A (en) | Method of treating lesions in a nervous system | |
| US6407209B1 (en) | Interferon-induced human protein in pure form, monoclonal antibodies thereto and test kits containing these antibodies | |
| KR890001828B1 (ko) | 인터페론-α형의 폴리펩티드의 제조방법 | |
| KR910009901B1 (ko) | 하이브리드 인간 백혈구 인터페론 | |
| KR970007862B1 (ko) | 인체 면역글로불린 e결합인자와 관련된 폴리 펩타이드를 코드화하는 유전자, 이러한 유전자가 삽입된 벡터 pcl2,이러한 벡터로 형질 전환된 에스케리키아콜라이숙주 및 이의 제조방법 | |
| CS273181B2 (en) | Method of escherichia coli cells production that are capable to produce mature human leucocytic interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: NOVARTIS AG |
|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: NOVARTIS AG |